Involvement of proteolytic activation of protein kinase R in the apoptosis of PC12 pheochromocytoma cells.
Protein kinase R (PKR) is a serine/threonine-specific protein kinase implicated in the control of cell growth, differentiation, interferon-induced antiviral response, and induction of apoptosis. It is activated by various stress signals and growth factors. Activated PKR phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2alpha), thereby inhibiting the initiation of translation. PKR also mediates the activation of several transcription factors (STAT1, p53, and NFkappaB) regulating both pro- and antiapoptotic mechanisms. In the present work, we studied the signaling pathways leading to PKR activation and apoptosis in PC12 rat pheochromocytoma cells, a model system of neuronal differentiation and cell death. We found that administration of various apoptosis inducing agents and conditions (serum starvation, anisomycin, LY294002, etoposide, and cisplatin) led to the proteolytic cleavage of PKR in PC12 cells. This cleavage was in strong correlation with the time kinetics of DNA fragmentation and morphological alterations characteristic of apoptosis. PKR was activated by the proteolytic cleavage: increased phosphorylation of eIF2alpha was found to run parallel with PKR cleavage. The activation of caspase-3 and caspase-9 was stimulated by all apoptosis inducing agents used in this study. The activation of caspase-3 preceded the cleavage of PKR after serum withdrawal, anisomycin and etoposide treatment, while coincided with it in cells treated with LY294002 or cisplatin. These observations suggest that early activation of caspase-3 is upstream of PKR proteolysis and that proteolytic activation of PKR may play a general role in the apoptosis of PC12 cells induced by various forms of cellular stress.
Pap
Marianna
M
Department of Medical Biology, Medical School, University of Pécs, Szigeti 12, 7624, Pécs, Hungary.
Szeberényi
József
J
D000310:Adrenal Gland Neoplasms / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D000841:Anisomycin / Q000494:pharmacology; D017209:Apoptosis; D053148:Caspase 3 / Q000378:metabolism; D053453:Caspase 9 / Q000378:metabolism; D002867:Chromones / Q000494:pharmacology; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D053938:DNA Fragmentation; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D016716:PC12 Cells; D010447:Peptide Hydrolases / Q000378:metabolism; D010673:Pheochromocytoma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology*; D011499:Protein Processing, Post-Translational / Q000502:physiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D051381:Rats; D019892:eIF-2 Kinase / Q000378:metabolism* / Q000502:physiology*
D002867:Chromones; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D009025:Morpholines; D011500:Protein Synthesis Inhibitors; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D000841:Anisomycin; D019892:eIF-2 Kinase; D010447:Peptide Hydrolases; D053148:Caspase 3; D053453:Caspase 9